Do we know the status of that? Has the GLP study for Hema been initiated by CRL? When was it started? Is it near complete? Does anyone know?

So the GLP safety study is underway in the new facility with the company they partnered with recently? Has this all been confirmed? Sorry haven't been following this closely to protect my own sanity. :)

Is the increase in A/S to 3.5 billion cover the shares to PM for the reverse merger? Or how many and when are those addtional shares convertible?

I'm out dangit on a 10% loss this time around. Still think and wanna believe there's money to be made here. I'm gonna keep watching...

CAN'T ARGUE WITH YOU THERE. WHAT DO YOU THINK THEIR MOTIVATION IS FOR FILING AND BECOMING COMPLIANT? THOUGHTS?

LET'S SEE HOW THIS PLAYS OUT THE REST OF THE WEEK. I EXPECT SOME DILUTION. YOU DON'T THINK THIS IS A GOOD PLAY AT THESE LEVELS? INTERESTED TO GET YOUR TAKE ON IT. I'M THINKING .0028 EOD. ANYBODY GOT AN L2?

LET'S NOT FORGET...AWESOME SHARE STRUCTURE HERE!!! THIS DILUTION MEANS NOTHING - AS LONG AS IT DOESN'T CONTINUE THE REST OF THE WEEK! THIS COULD ACTUALLY BE A SIGN THAT THOSE FINANCIALS ARE COMING!

http://www.otcmarkets.com/stock/IFCR/profile
Shares Outstanding 397,002,718 a/o Mar 18, 2015
Float 150,340,066 a/o Mar 18, 2015
Authorized Shares 2,000,000,000 a/o Mar 18, 2015

THIS IS UNDERVALUED HERE. BOTTOMS IN. I'M BACK AT .0022!

GO $IFCR

IFCR TIMELINE (IHUB):

4/15 - 10-K'S SHOULD BE OUT SOON THEN BOOM!
5/15 - C'MON DAVID WHERE ARE THE FINS?
6/15 - THIS IS STARTING TO LOOK LIKE A SCAM!
7/15 - WTF GUESS ALL THAT ABOUT GETTING UP TO DATE WAS B.S.!
8/15 - PPS .0016

-OR-

4/15 - 10-K'S SHOULD BE OUT SOON THEN BOOM!
5/15 - C'MON DAVID WHERE ARE THE FINS?
6/15 - THIS IS STARTING TO LOOK LIKE A SCAM!
7/15 - FINS OUT! WHERES THE REVENUE! OMG HOW ARE THEY GOING TO SATISFY ALL THAT DEBT!
8/15 - PPS .0016

YOU'RE WELCOME! :)

OUCH!!! .0032!!! DOWN 29%!!! LOW TO MID .0020'S SHORTLY! DON'T HOLD YOUR BREATH WAITING FOR THOSE FILINGS! :(

David is going to take his time with the more recent filings. These are not going to be pretty. Don't get caught holding the bag with this one!

LOL! :) Nice!

What is going on here? Nice volume!

Good luck to you. Hopefully for everyone still holding you are right and I am wrong! .0030's coming for sure next week! :(

For IFCR? Probalbly late 2015 right before the reverse split in 2016!!! :)

I think you need to read between the lines on this one a little bit...

"On other matters relating to structure," Fuselier continued, "as a corporate strategy for calendar 2015, we do not anticipate, at this time, that a reverse split is advisable or practical. We anticipate that a reverse may however occur in calendar 2016."

Mr. Fuselier completed his comments regarding the IFCR structure by saying, "Most companies in the small public market require regular, recurring, forms of capital formation to operate. Integrated Freight is no exception and carries with it varying types of debt that may convert into shares of our common stock. Recently, some of these debt holders requested conversions as provided under existing contracts and the Company issued common stock pursuant to the contract terms.


This company is still almost 2 years behind in filings. How much debt accrued in recent years you think is still left to convert - I'm thinking quite a bit. :(

Take profits while you can here and don't invest more than you can afford to lose with this one. :( IMO.

Good question - financials probably won't be good IMO. :( I'd say take profits now, this will likely be back in the high 20's or low 30's in a couple of weeks. :(

I would agree. I originally thought early to mid-Spring, but this company is like my mechanic, always takes longer than expected.

Some volume would be nice! :) $IFCR

Good post thanks. That would certainly explain his desire to become current. I had no idea S/S was this fantastic. I see 2 to 3 cents fairly soon. Certainly anything under .0040 is a bargain! Loading time! $IFCR

I agree but why even mention a R/S when the share structure is what it is? What am I missing?

This is going back to .0050!!!! And that's just for starters! BOOM!!! Let's go $IFCR!

Where are all the big guns (e.g. M0NEYMADE, STERVC, RayinBrooklyn)? Are they no longer playing this?

You better wear gloves then because this is crap at this point. This is become nothing but a pile of dead money. Someone help me please; please share an upside to owning this ticker at this point?

I'll admit I started a position on this based on recent events and didn't do my upfront DD on this as well as I should have. That said, while I understand your commentary on overall company value, based on the previous LUK PR re: FXCM, can news Thursday really be that negative such that it would send the price of this below $2? What am I missing? How can this ticker not move up on Friday?

ty much appreciated

Can someone post L2 quotes?

Dude there's this thing called google maps and I don't know if you are looking at the same building I am looking at but the building is pretty damn huge and nice. There's a pretty good sized insurance agency in there, a dentist office, psychiatric doctors, a substantial real estate office, and four huge floors of suites and offices! I wish half of my pinks had digs like that! Looks like there is plenty of space there to me!

Good post. Want to make sure we are on the same page though.

On 9/10 PR stated: 'The Company was informed that before it is cleared to initiate a clinical trial, it must submit additional safety data from experiments conducted in a GLP certified laboratory'.

On 1/14 PR stated: 'Currently FDA is reviewing protocols submitted by the Company for conducting an additional GLP safety study before clinical trials can begin'.

That 1/14 PR is almost 2 months old. I don't see any other company information regarding HemaXellerate since 1/14.

In those 2 months that have passed, do you think it's possible protocol has been approved and those GLP tests are underway as of today? My thought is the company wouldn't announce that they were, as although that may indicate progress to some, most investors would just view it as another fluff PR. Perhaps this is closer than one may think given some of the other events that have happened since the 1/14 PR.

I don't know either way, but I'm just thinking (or hoping) RGBP is closer than you infer. Thoughts?

Regen BioPharma Inc. Files Patent Application for Treatment of Myelodysplastic Syndrome Utilizing Gene Silencing Therapy


Company Developing Drug Candidate to Potentially Augment HemaXellerate Therapy for Treating Aplastic Anemia

SAN DIEGO, CA, Mar 03, 2015 (Marketwired via COMTEX) -- Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.
Myelodysplastic Syndrome (MDS) is a collection of diseases that include aplastic anemia, a condition where the bone marrow does not produce sufficient numbers of blood cells. Survival for patients with myelodysplastic syndrome is shorter than survival for patients with lung cancer, as treatment options for these patients with MDS are limited.

Patients with myelodysplastic syndrome are often older and cannot tolerate the side effects associated with aggressive chemotherapy regimens (current baseline form of treatment). As a result they are given palliative therapies, like blood transfusions, because curative options do not exist for most patients.

"Regen has filed a patent on a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action of the therapeutic in development is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells," said Dr. Thomas Ichim, Chief Scientific Officer of Regen BioPharma.

There are currently 3 drugs approved by the FDA for the treatment of myelodysplastic syndrome: Revlimid (Celgene) with $3.767 billion sales in 2012; Vidaza (Celgene) with $823 million in sales in 2012; and Dacogen (Jansen) which generated royalty revenue of $60 million in 2011. Regen sees each of these 3 drugs having benefited a limited patient population. However, Regen believes its gene silencing approach may serve a broader patient population in a more effective manner.

"We are pleased to announce the expansion of the Company's aplastic anemia platform to include myelodysplastic syndromes. While our HemaXellerate product addresses immunological causes of aplastic anemia, the current differentiation product addresses molecular causes," said David Koos, President, CEO, and Chairman of Regen BioPharma. "We see this expanded approach strengthening the treatment model."

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

It's Illinois. For the right price you never know! :)

Stay away and wait for .0001's in April. 0003's right now aren't real unfortunately. Then wait/hope for news and sell before the R/S. If news happens sooner chase, otherwise way too risky right now. IMO.

Buying more at .0022 tomorrow.

I wouldn't want to still be holding this on Friday! :(

Good summary IMO. I still believe this is closer than you infer however, though it would be nice to see a concrete PR stating fulfillment of the GLP request by the FDA, or some status of accomplishment.

I agree. Just the beginning here. This spring (could be this month even!) RGBP is going to get FDA approval and explode. Koos setting this up nicely! Such a low share structure here! Boomage!! $RGBP

Based on company press releases the auditors should have had this for a while now. Thursday is just my 'line in the sand' timeframe! :) Though depending on where this is at the end of the week the line could be blown out till Tuesday of the following week. :) But that is definitely where I will be out if there is no news by then. Everyone should have taken some profits last week, and the bottom shouldn't fall out of this anytime soon, so holding till Tuesday of the following week isn't going to kill me.

This is also on the cusp of a turd. If fins aren't out by this Thursday that indicates to me a messy situation, and I'll be out as will a lot of others. Not taking a loss on this one. 20's should hold this week.

5's are a thing of the past. 4's going forward are going to be rare. 2's and 3's is where this is going to churn for awhile, with pretty strong support at .0002. .0002 is your entry IMO. GLTA.

Publicly-traded pharmaceutical companies are required to make certain information about themselves available to investors and regulators when that information would be material to the decision of the average shareholder to buy or sell shares. At a minimum, compliance with securities laws requires public companies to make such information available in periodic annual and quarterly reports (see 10-Q, 10-K). SUCH REPORTS MUST BE TRUTHFUL, ACCCURATE, AND NOT OMIT MATERIAL INFORMATION. I'm done arguing with you and your not going to make a dime off any more emails from me.

If the company (in conjunction with the FDA) has completed it's evaluation and there is bad news, the question becomes when must the company reveal it. It's my understanding two principal events create a duty to disclose material facts. Those are:
1. Trading in the biotech's stock.
2. Statements by the company that attempt to mislead w/o disclosure.
The first of these events presents a bright line test: a company can easily determine when it is buying or selling its own stock and, in most cases, should be able to determine when its principal officers or its directors buy or sell. In either case, a company having material information about bad test results must publicly disclose that information before the trades occur.
The second disclosure trigger is somewhat more difficult to apply. But in a case where RGBP has reached a conclusion that test results on Hema or dCellVax are negative, it may, as a practical matter, be difficult to provide any progress report on the product to the investment community that fails to include this bad news without the report being arguably incomplete or misleading. News from RGBP continues to be that this is moving forward, albeit not as fast as we shareholders would like.